Category: Corona Virus

Page 121«..1020..120121122123..130140..»

Carnival ruled negligent over cruise where 662 passengers got COVID-19 early in pandemic – ABC News

October 25, 2023

A cruise operator that failed to cancel a voyage from Sydney that led to a COVID-19 outbreak has been ruled negligent in an Australian class-action case

By

ROD McGUIRK Associated Press

October 25, 2023, 2:51 AM ET

3 min read

CANBERRA, Australia -- A cruise operator that failed to cancel a voyage from Sydney that led to a major COVID-19 outbreak was ruled negligent in its duty of care to passengers in an Australian class-action case Wednesday.

The Ruby Princess ocean liner left Sydney on March 8, 2020, with 2,671 passengers aboard for a 13-day cruise to New Zealand but returned in 11 days as Australias borders were closing. COVID-19 spread to 663 passengers and claimed 28 lives.

Passenger Susan Karpik was the lead plaintiff in the case against British-American cruise operator Carnival and its subsidiary Princess Cruises, the ship's owner.

Federal Court Justice Angus Stewart ruled that Carnival had been negligent as defined by Australian consumer law by allowing the cruise to depart in the early months of the pandemic. He said Carnival had a duty to take reasonable care of her health and safety in regard to COVID-19.

I have found that before the embarkation of passengers on the Ruby Princess for the cruise in question, the respondents knew or ought to have known about the heightened risk of coronavirus infection on the vessel and its potentially lethal consequences and that their procedures for screening passengers and crew members for the virus were unlikely to screen out all infectious individuals, Stewart said.

Carnival had already experienced outbreaks on its cruises in the previous month aboard the Grand Princess off California and the Diamond Princess off Japan, the judge said.

Carnival had failed to explain why it offered free cancellation for all cruises worldwide leaving from March 9 the day after the Ruby Princess departed and suspended all cruises on March 13, he said.

To the respondents knowledge, to proceed with the cruise carried significant risk of a coronavirus outbreak with possible disastrous consequences, yet they proceeded regardless, Stewart said.

Susan Karpik had sued Carnival for more than 360,000 Australian dollars ($230,000).

However, she was only awarded her out-of-pocket medical expenses of AU$4,423.48 ($2,823.28) for reasons including that the judge did not accept she suffered from long COVID and that Carnival had refunded all the passengers fares.

But she said she was happy with the outcome.

I was very pleased with that finding. And I hope the other passengers are pleased with that finding too, she told reporters outside court.

I hope the finding brings some comfort to them because theyve all been through the mill and back, she added.

Her lawyer Vicky Antzoulatos said other passengers who suffered worse consequences from their sickness could expect larger payouts.

While Susan Karpik's symptoms were relatively mild, her husband Henry Karpik spent two months in hospital and almost died from his infection.

Susans husband was very catastrophically injured, so we expect that he will have a substantial claim, and that will be the same for a number of the passengers on the ship, Antzoulatos said.

Each passenger will have to prove their claims unless Carnival agrees to settle, she said.

Its been a long time coming and a very comprehensive victory for the passengers on the Ruby Princess, Antzoulatos said.

Carnival Australia said in a statement it was considering the judgment in detail.

The pandemic was a difficult time in Australias history, and we understand how heartbreaking it was for those affected, Carnival said.

Excerpt from:

Carnival ruled negligent over cruise where 662 passengers got COVID-19 early in pandemic - ABC News

COVID-19 Vaccine Protects Against the Corona Virus in Patients … – BioSpace

October 25, 2023

The first-of-its-kind study was conducted in Israel byKSM - Maccabi's Research and Innovation Center. The results were published in the peer-reviewed journal Viruses.

TEL AVIV, Israel, Oct. 24, 2023 /PRNewswire/ -- A retrospective study undertaken by Maccabi KSM Research in Israel has revealed that the Pfizer COVID-19 vaccine offers the same level of protection against the virus for patients with Celiac Disease as it does for those without this chronic condition.

Throughout the pandemic, there were concerns surrounding whether individuals with Celiac Disease would generate an adequate immune response to COVID-19 vaccines. These concerns stemmed from earlier research, which indicated reduced vaccine responsiveness among children with Celiac Disease to the hepatitis B vaccine. Furthermore, the absence of data from COVID-19 vaccine clinical trials involving individuals with chronic conditions, including Celiac Disease, exacerbated these uncertainties.

Now, researchers in Israel and New York have concluded a real-world, population-based study to assess the effectiveness of the BNT162b2 mRNA COVID-19 vaccine (Pfizer vaccine) against SARS-CoV-2 (COVID-19). This study was carried out in 2021 during the pandemic peak when COVID-19 tests were readily accessible and often mandated by government authorities. The study's findings were recentlypublished in the journal Viruses.

The retrospective study, pulled on anonymous data from Maccabi Healthcare Services, included 5,381 Maccabi members over the age of 12 with Celiac Disease and 14,939 controls. All Celiac Disease patients had received two COVID-19 vaccine doses.

The results showed no difference in the vaccine effectiveness between the groups.There was also no significant difference between patients with controlled and uncontrolled Celiac Disease and in patients recently diagnosed with Celiac Disease.

The study was led by Dr. Tal Patalon and Dr. Amir Ben Tov from KSM Research and Innovation Center, Israel, in cooperation with Dr. Benjamin Lebwohl from the Celiac Disease Center at Columbia University Irving Medical Center, New York.

Dr.Patalon, head of KSM Research and Innovation Center, said, "This research proves the importance of real-world evidence in healthcare, where big-data studies can retrospectively focus on small and particular groups of individuals, often missed in clinical trials."

Media Contact Dvir Assouline, dvir@propr.us

View original content:https://www.prnewswire.com/news-releases/covid-19-vaccine-protects-against-the-corona-virus-in-patients-with-celiac-disease-301966302.html

SOURCE KSM Research and Innovation Center

Originally posted here:

COVID-19 Vaccine Protects Against the Corona Virus in Patients ... - BioSpace

Weakened innate immunity may increase risk of severe COVID-19 – News-Medical.Net

October 25, 2023

During severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activated macrophages, dendritic cells, neutrophils, and natural killer cells are the first defense against infection. These immune effectors trap and ingest the virus, kill infected epithelial cells, or produce anti-viral cytokines. Evidence suggests that aging, obesity, and mental illness can lead to weakened innate immunity and, thus, are all associated with elevated infection and severe disease progression of coronavirus disease 2019 (COVID-19). Innate immune defense networks play a fundamental role in suppressing viral replication, infection establishment, and viral pathogenesis of SARS-CoV-2 and other respiratory viruses.

Source:

Journal reference:

Wang, Z., et al. (2023). Role of innate immunity in SARS-CoV-2 infection. Biosafety and Health. doi.org/10.1016/j.bsheal.2023.08.005.

See the article here:

Weakened innate immunity may increase risk of severe COVID-19 - News-Medical.Net

Carnival ruled negligent over cruise where 662 passengers got … – Quartz

October 25, 2023

CANBERRA, Australia (AP) A cruise operator that failed to cancel a voyage from Sydney that led to a major COVID-19 outbreak was ruled negligent in its duty of care to passengers in an Australian class-action case Wednesday.

Why the future of streaming may not involve Netflix or Disney+ | What's next for streaming?

The Ruby Princess ocean liner left Sydney on March 8, 2020, with 2,671 passengers aboard for a 13-day cruise to New Zealand but returned in 11 days as Australias borders were closing. COVID-19 spread to 663 passengers and claimed 28 lives.

Passenger Susan Karpik was the lead plaintiff in the case against British-American cruise operator Carnival and its subsidiary Princess Cruises, the ship's owner.

Federal Court Justice Angus Stewart ruled that Carnival had been negligent as defined by Australian consumer law by allowing the cruise to depart in the early months of the pandemic. He said Carnival had a duty to take reasonable care of her health and safety in regard to COVID-19.

I have found that before the embarkation of passengers on the Ruby Princess for the cruise in question, the respondents knew or ought to have known about the heightened risk of coronavirus infection on the vessel and its potentially lethal consequences and that their procedures for screening passengers and crew members for the virus were unlikely to screen out all infectious individuals, Stewart said.

Carnival had already experienced outbreaks on its cruises in the previous month aboard the Grand Princess off California and the Diamond Princess off Japan, the judge said.

Carnival had failed to explain why it offered free cancellation for all cruises worldwide leaving from March 9 the day after the Ruby Princess departed and suspended all cruises on March 13, he said.

To the respondents knowledge, to proceed with the cruise carried significant risk of a coronavirus outbreak with possible disastrous consequences, yet they proceeded regardless, Stewart said.

Susan Karpik had sued Carnival for more than 360,000 Australian dollars ($230,000).

However, she was only awarded her out-of-pocket medical expenses of AU$4,423.48 ($2,823.28) for reasons including that the judge did not accept she suffered from long COVID and that Carnival had refunded all the passengers fares.

But she said she was happy with the outcome.

I was very pleased with that finding. And I hope the other passengers are pleased with that finding too, she told reporters outside court.

I hope the finding brings some comfort to them because theyve all been through the mill and back, she added.

Her lawyer Vicky Antzoulatos said other passengers who suffered worse consequences from their sickness could expect larger payouts.

While Susan Karpik's symptoms were relatively mild, her husband Henry Karpik spent two months in hospital and almost died from his infection.

Susans husband was very catastrophically injured, so we expect that he will have a substantial claim, and that will be the same for a number of the passengers on the ship, Antzoulatos said.

Each passenger will have to prove their claims unless Carnival agrees to settle, she said.

Its been a long time coming and a very comprehensive victory for the passengers on the Ruby Princess, Antzoulatos said.

Carnival Australia said in a statement it was considering the judgment in detail.

The pandemic was a difficult time in Australias history, and we understand how heartbreaking it was for those affected, Carnival said.

Read more here:

Carnival ruled negligent over cruise where 662 passengers got ... - Quartz

Viral rebound common in lung transplant recipients treated with … – News-Medical.Net

October 25, 2023

Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. The study prospectively followed four LTx recipients. Clinical characteristics, viral RNA dynamic in throat swabs, and tacrolimus blood concentration were monitored regularly. All four LTx recipients, aged 3574 years, were not vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They got coronavirus disease 2019 (COVID-19) after more than one week of admission during the era of Omicron.

All cases received nirmatrelvir/ritonavir (NM/r) within two days of infection, and the relative viral RNA copies dropped quickly. Viral load rebound was observed in all four cases after discontinuation of the first five days of NM/r treatment. Three of them received another 5-days antiviral therapy with NM/r. The duration of positive viral PCR testing was 25-28 days. None of them progressed into severe or critical COVID-19. Tacrolimus was stopped 12 h before NM/r and held during the 5-day course of antiviral therapy. Blood concentration of tacrolimus were maintained at a baseline level during these five days.

Tacrolimus was reinitiated at its baseline daily dose 3-4 days after NM/r therapy. However, during the second round of antiviral therapy with NM/r, the concentration of tacrolimus fluctuated wildly. In conclusion, the 5-day course of NM/r treatment was not sufficient for LTx recipients and the viral rebound was common. More data are needed to clarify whether LTx recipients with SARS-CoV-2 viral rebound could benefit from additional treatment with NM/r.

Source:

Journal reference:

Li, H., et al. (2023). Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2. Biosafety and Health. doi.org/10.1016/j.bsheal.2023.08.004.

Link:

Viral rebound common in lung transplant recipients treated with ... - News-Medical.Net

USPTO Report on COVID-19 Diagnostics Shows Outsized Impact of … – IPWatchdog.com

October 25, 2023

[F]ederal funding mechanisms under Bayh-Dole [had] a robust impact on COVID-19 R&D, [and] small businesses were by far the top beneficiaries of Bayh-Doles impact on innovation during the pandemic.

Source: USPTO Report

On October 23, the U.S. Patent and Trademark Offices (USPTO) Office of the Chief Economist (OCE) published a report detailing patent application filing trends at the USPTO related to COVID-19 diagnostics technologies. The OCE found that filing activity surged following the arrival of the novel coronavirus in early 2020, with much of that increase driven by small companies and research institutions. The report found further evidence suggesting that federal funding had a significant impact on driving innovation into COVID-19 diagnostics at small R&D entities.

The fourth quarter of 2021 saw the publication of 167 U.S. patent applications covering COVID-19 diagnostics technologies, according to the OCEs report. This represents 20% of the U.S. patent applications found by the OCEs keyword search methodology, the peak quarter for publication of COVID-19 diagnostic patent applications since the pandemic began. While COVID-19 diagnostics only account for 1.4% of all patent application filings in medical diagnostics, COVID-19 diagnostics represented 30% of all COVID-19-related patenting activity.

Overall, the OCEs report identified 824 U.S. patent applications covering COVID-19 diagnostics and filed between December 2019 and April 2023. Companies accounted for 58% of all filings, and of the total filings from corporate R&D applicants, 64% were filed by companies qualifying as small entities. Universities, research institutions and hospitals accounted for 27% of all COVID-19 diagnostic filings, and 82% of patent applications in this group were also filed by small entities. Perhaps surprisingly, the OCEs report noted that unaffiliated individuals accounted for 13% of COVID-19 diagnostics patent applications identified in the survey.

The major contributions of small and micro entities to innovation in COVID-19 diagnostics also runs counter to larger trends, underscoring the importance of small businesses to research and development into COVID-19 diagnostics. The OCEs report points out that only 24% of all U.S. patents issued during 2022 went to companies qualifying for small or micro entity discounts. Conversely, small entities filed the most COVID-19 diagnostics patent applications among every applicant group except for government agencies.

While government agencies were only assigned 15 of the COVID-19 diagnostics filings identified by OCE, the report assessed government interest statements on patent applications showing that federal funding significantly contributed to developments in the sector. OCE found 88 patent applications, or 10.7% of all COVID-19 diagnostics filings, containing such a statement indicating federal funding contributions to the underlying invention. Small and micro entities accounted for 81% of the filings, indicating not only that federal funding mechanisms under Bayh-Dole were having a robust impact on COVID-19 R&D, but that small businesses were by far the top beneficiaries of Bayh-Doles impact on innovation during the pandemic.

Analyzing Cooperative Patent Classification (CPC) subclass codes, the OCEs report found that nearly half of all COVID-19 diagnostics filings were classified as analyzing materials by chemical and physical properties. Aside from measuring enzymes, nucleic acids and microorganisms, no other CPC subclass was seen on more than 20% of COVID-19 diagnostics filings. The OCEs report notes a higher than expected showing for health care informatics, a CPC subclass code appearing on 12.4% of COVID-19 diagnostics filings. The report indicates that this number reflects in part the impact of in-home diagnostics tests that became popular during the pandemic.

The OCEs report also reflects the fact that COVID-19 diagnostics inventions are not always separate and distinct from COVID-19 vaccines and therapeutics. For example, 8.6% of public filings for COVID-19 diagnostics fell into the CPC subclass for specific therapeutic activity of chemical compounds or medicinal preparations.

Analyzing international patent filing data available through the Derwent World Patent Index, the OCEs report found that the largest number of patent families related to COVID-19 diagnostics were filed at the China National Intellectual Property Administration (CNIPA). The CNIPA saw 2,643 patent families covering COVID-19 diagnostics during the pandemic, far more than the 784 such patent families filed at the second-place USPTO. Patent Cooperation Treaty (PCT) international filings accounted for 35% of the COVID-19 diagnostics filings tracked by the OCEs survey, with that number expected to rise due to the 30-month national phase period under PCT for selecting additional countries for national filings.

Read the original:

USPTO Report on COVID-19 Diagnostics Shows Outsized Impact of ... - IPWatchdog.com

A Case of Longitudinally Extensive Transverse Myelitis Following … – Cureus

October 25, 2023

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

Read the original post:

A Case of Longitudinally Extensive Transverse Myelitis Following ... - Cureus

CDC head makes case for vaccinations – NJ Spotlight News

October 25, 2023

Request blocked. We can't connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner. If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation. Generated by cloudfront (CloudFront)Request ID: iYp_UlZFYhtEpMneSxxbbMEzE7TDkcbbkljDlHUKWtFvwX48R2R3Yw==

Read the original:

CDC head makes case for vaccinations - NJ Spotlight News

COVID-19 update 10-23-23 – Suffolk County Government (.gov)

October 25, 2023

Suffolk County reported the following information related to COVID-19 on October 23, 2023

According to CDC, hospital admission rates and the percentage of COVID-19 deaths among all deaths are now the primary surveillance metrics.

COVID-19 Hospitalizations for the week ending October 14, 2023

Daily Hospitalization Summary for Suffolk County From October 20, 2023

NOTE: HOSPITALS ARE NO LONGER REPORTING DATA TO NYSDOH ON WEEKENDS OR HOLIDAYS.

Fatalities occurring in Suffolk County (Data showing fatalities by place of residence is archived as of 10/12/23 and is no longer being updated)

COVID-19 Case Tracker October 20, 2023

Note: As of May 11, 2023, COVID-19 Community Levels (CCLs) and COVID-19 Community Transmission Levels are no longer calculatable, according to the Centers for Disease Control and Prevention.

* As of 4/4/22, HHS no longer requires entities conducting COVID testing to report negative or indeterminate antigen test results. This may impact the number and interpretation of total test results reported to the state and also impacts calculation of test percent positivity. Because of this, as of 4/5/22, test percent positivity is calculated using PCR tests only. Reporting of total new daily cases (positive results) and cases per 100k will continue to include PCR and antigen tests.

COVID-19 Vaccination Information

Last updated 5/12/23

Vaccination Clinics

As of September 12, 2023, the Suffolk County Department of Health Services is not authorized to offer COVID-19 vaccines to ALL Suffolk County residents.

The department will offer the updated vaccine to only uninsured and underinsured patients through New York State's Vaccines for Children program and Vaccines for Adults program, also known as the Bridge Access Program.

Those with insurance that covers the COVID-19 vaccine are encouraged to receive their vaccines at their local pharmacies, health care providers offices, or local federally qualified health centers.

The department has ordered the updated COVID-19 vaccine and will announce when the vaccine becomes available.

FOR HEALTHCARE PROVIDERS

New York State Links

CDC COVID Data Tracker Rates of laboratory-confirmed COVID-19 hospitalizations by vaccination status

For additional information or explanation of data, click on the links provided in throughout this page.

The rest is here:

COVID-19 update 10-23-23 - Suffolk County Government (.gov)

Sensory Neural Hearing Loss as a Complication of COVID-19 and … – Cureus

October 25, 2023

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

Link:

Sensory Neural Hearing Loss as a Complication of COVID-19 and ... - Cureus

Page 121«..1020..120121122123..130140..»